Lung Support News
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
World TB Day and Infection Control Resources in New York City to Help Prevent New Cases
The New York City Department of Health and Mental Hygiene (NYC Health) warns that tuberculosis (TB) is still a life-threatening problem in the city. As recently as 2022, the agency reports there were 536 confirmed TB cases, including some involving multi-drug resistant (MDR) TB, and that 100% of NYC neighborhoods had at least one TB case. TB is caused by a bacterium known as Mycobacterium ...
-
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
Beyond Air, Inc. (NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
N8 Medical Announces First-in-Human Use of its CeraShield™ Endotracheal Tube
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...
-
World TB Day and Preventing New Cases in Healthcare Facilities and Correctional Institutions in Puerto Rico
World TB Day is recognized in Puerto Rico and across the globe on March 24th. The date of this annual event was chosen to coincide with the date that Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the cause of tuberculosis (TB), back in 1882. The Centers for Disease Control and Prevention (CDC) describes World TB Day as a time to educate the public about the impact of TB ...
-
It All Starts With Patient Safety at Medovate
When Medovate was spun out of the National Health Service (NHS) in 2017, one of the key priorities was to ensure that each medical device the company developed added real value to patient safety. The company mission is to “improve patient care and safety by supplying innovative Medtech solutions inspired by clinicians and developed in partnership with the NHS.” Through a unique ...
By Medovate
-
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System
Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off mechanical ventilation and breathe on ...
-
Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study
Patient survival doubles when Seraph 100 is used earlier during ICU stay MARTINEZ, Calif. – Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released ...
-
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine. ...
-
FDA Grants the Hemolung® De Novo Clearance
PITTSBURGH – (BUSINESS WIRE) – November 15, 2021 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the Company De Novo clearance for the Hemolung Respiratory Assist System. The Hemolung ...
-
Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available
Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital ...
-
National Patient Safety Agency Alert Concerning Nebulisers
The National Patient Safety Agency recently issued an alert (NatPSA/2021/003/NHSPS) necessitating organisations to “purchase sufficient powered nebuliser devices for use across the organisation; to remove the need for medical air to drive nebulisers via a flowmeter”. It states that all NHS hospitals are required to be fully compliant by the 16th November 20211. Aerogen, vibrating ...
By Aerogen
-
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...
By Benevolent
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...
-
Berlin Heart Today Announces CE Approval and First Implantation of an Innovative Bridging Solution for Single Ventricle Patients
Berlin, March 2021: With the first-in-man implantation of the Berlin Heart Venous Cannula at the LMU University Hospital Munich (Grosshadern), Germany, Berlin Heart offers patients with a failing Fontan circulation a unique chance to survive the waiting time for a donor heart. These patients are in a life-threatening condition: their health has deteriorated so much that they desperately need a ...
-
IONICON Analyzers at the Forefront of International COVID-19 Testing Research
A non-invasive test for COVID-19 with instant results would be a gamechanger in the efforts against COVID-19. Breath analysis shows a great potential for a rapid, non-invasive detection of COVID-19 infections. Follow our journey around the world, where we shine a light on current research projects where IONICON PTR-TOF instruments are deployed fighting this global pandemic by testing breath for ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
-
Liberate Medical Reports Positive Pilot Trial Results of VentFree Respiratory Muscle Stimulator
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease. The use of higher dexamethasone doses, with potentially additional and desired immunological effects, is limited due the presence of toxic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you